← Back to headlines
Aurinia Pharmaceuticals Eyes Growth Following LUPKYNIS Patent Settlement with Teva
Analysts evaluate whether Aurinia Pharmaceuticals' recent patent settlement for its kidney disease drug LUPKYNIS with Teva could drive significant stock gains for investors.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
UNICEF Report Finds 20 Million Children Annually Face Online Sexual Exploitation
53m ago
Genetically Modified Pig Kidney Keeps US Patient Alive for Record Nine Months
1h ago
Pentagon Temporarily Rescinds Testosterone Screening Guidance for Troops
3h ago
RFK Jr. Allegedly Requested Removal of Measles Deaths From CDC Tally
4h ago